Regeneron Pharmaceuticals, Inc. Stock

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
894.1 USD -0.49% Intraday chart for Regeneron Pharmaceuticals, Inc. -5.27% +1.80%
Sales 2024 * 13.91B Sales 2025 * 14.9B Capitalization 96.56B
Net income 2024 * 4.29B Net income 2025 * 4.54B EV / Sales 2024 * 6.26 x
Net cash position 2024 * 9.5B Net cash position 2025 * 14.04B EV / Sales 2025 * 5.54 x
P/E ratio 2024 *
24.5 x
P/E ratio 2025 *
23.1 x
Employees 13,450
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.68%
1 week-4.25%
Current month-6.64%
1 month-6.83%
3 months-3.71%
6 months+7.02%
Current year+2.31%
More quotes
1 week
895.09
Extreme 895.09
937.87
1 month
895.09
Extreme 895.09
979.26
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
478.40
Extreme 478.4
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 54 02-12-31
Members of the board TitleAgeSince
Director/Board Member 71 10-11-11
Chief Executive Officer 71 88-01-07
Director/Board Member 82 91-05-31
More insiders
Date Price Change Volume
24-04-16 894.1 -0.49% 615,755
24-04-15 898.6 -0.68% 656,427
24-04-12 904.7 -1.70% 665,281
24-04-11 920.3 -1.70% 617,176
24-04-10 936.2 -0.81% 389,765

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
898.6 USD
Average target price
1,028 USD
Spread / Average Target
+14.45%
Consensus